Corporate Responsibility Statement

Our Commitment:

Flexipharm Austrading Limited is committed to operating with integrity and delivering products through innovation and quality to healthcare professionals within the NHS and independent hospitals

We realise our corporate responsibilities across the UK and are committed to operating the business in a responsible manner that seeks to minimise environmental impact, while promoting the efficient and responsible use of global resources.

Flexipharm Austrading Limited focuses on distributing improved versions of generic injectable drugs to the UK that meet the rigorous standards of quality, efficacy and safety set by the MHRA, including compliance to Good Manufacturing Practice (GMP) and Good Distribution Practice. The products we focus on have one or more of the following challenges;

• Concerns around security of ongoing supply and/or
• Where the current presentation is not optimal for the needs of the NHS staff and/or
• Where the current presentations can contribute to medication errors

Our current portfolio is supplied in Type I moulded glass vials which do not break if dropped, they also include clear plastic shrink wrap, to protect healthcare professionals from drug product if a vial is cracked and a base cup to give the vial stability when placed on a flat surface and drug is extracted. Flexipharm Austrading Limited was the first company to use a “wrapper and base cup” for the key haematology-oncology drug arsenic trioxide. A focus on vials, as opposed to glass ampoules, helps eliminate a major cause of avoidable sharps injuries, reduces the cost and waste of using filter straws and filter needles, required to extract drug from glass ampoules, and helps hospitals comply with Health and Safety Regulations which mandate the use of “safer sharps” wherever possible.

Flexipharm Austrading Ltd are also aware of the importance of corporate social responsibility in the UK. This commitment is highlighted through the following activities:

• Advising and supporting the founders of Accelerating Clinical Trials for Patients, https://www.act4patients.com, ACT funds the established and globally significant UK trials networks TAP and IMPACT, in locations across the UK with a strong track record of accelerated recruitment and patient access to exciting new medicines.
• Working with wholesaler partners to supply products internationally to mitigate short term supply disruption or shortages.
• The sponsoring of programmes/providing speakers for the encouragement of the study of STEM subjects and careers in medicine at schools in the local area.
• The supply of medicines free of charge to bona fide healthcare professionals undertaking validated clinical/scientific research.
• Professional membership and support of professional bodies representing the different customer groups who use our products, e.g., British Oncology Pharmacists Association.
• Volunteering as welfare officers for local sports clubs.
• Contributing and supporting through membership and providing pro-bono advice to the trade body, the Ethical Medicines Industry Group for its initiatives with the NHS and government.

Michael Clark
Managing Director
November 2023